CareDx, Inc
CDNANASDAQ
CDNA·NASDAQ
Care. Dx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: Allo. Sure Kidney, Allo. Sure Heart, and Allo. Sure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cf. DNA) technology to assess the health of kidney, heart, and lung transplants, respectively. Allo. Map Heart: A gene expression-based solution specifically for heart transplant patients. Allo. Seq cf. DNA: A broader surveillance tool to measure dd-cf. DNA levels in the blood. Care. Dx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as Tru. Sight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and Allo. Seq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers Allo. Seq HCT for chimerism testing. Beyond diagnostics, Care. Dx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; Xyn. QAPI, focused on transplant quality tracking and waitlist management; and Allo. Care, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. Care. Dx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to Care. Dx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Care. Dx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: Allo. Sure Kidney, Allo. Sure Heart, and Allo. Sure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cf. DNA) technology to assess the health of kidney, heart, and lung transplants, respectively. Allo. Map Heart: A gene expression-based solution specifically for heart transplant patients. Allo. Seq cf. DNA: A broader surveillance tool to measure dd-cf. DNA levels in the blood. Care. Dx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as Tru. Sight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and Allo. Seq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers Allo. Seq HCT for chimerism testing. Beyond diagnostics, Care. Dx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; Xyn. QAPI, focused on transplant quality tracking and waitlist management; and Allo. Care, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. Care. Dx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to Care. Dx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.